via Epidemiology of stroke in Maputo, Mozambique. The chance to offer a low cost alternative to acute ischemic stroke may bring new interest on Strptokinase. The wide availability of this drug for cardiological units may offer an great opportunity. A need for a restriction of the indication is the main countermeasure to adopt. […]
May anti depressants be helpfull in stroke recovery ? also in non depressed subjects ? Double blind placebo controlled on benefit of prolonged release Levomilnacipran in ischemic stroke recovery. A phase II RCT sponsored by Pierre Fabre Medicament IRPF. First patient enrolled in France. Up to 90 participating centres, six Italian centres will join the […]
How can we monitor Dabigatran effects ? Dabigatran, like argatroban, does prolong the prothrombin time (PT) and partial thromboplastin time (PTT). It also prolongs the thrombin time (TT), which means it generates a false decrease in fibrinogen assay results, given that the fibrinogen assay is based on the TT. Dabigatran’s plasma concentration peaks about two […]
According to non official sources the national health care authorities in the last week abolished the formal need of triple form transcription in order to prescribe Clopidogrel for secondary prevention in non cardioembolic stroke. The need of a specialist to prescribe the drug with a so called “piano terapeutico” forced patients […]
on 30 August 2010 Ingelheim, Germany – Report: The European Society of Cardiology (ESC) today issued a revised version of guidelines for the management of atrial fibrillation (AF), including guidance on the role of thge new oral treatment, dabigatran etexilate, for the prevention of embolism in patients with atrial fibrillation (AF). At the same time, […]
strokefocus 
You must be logged in to post a comment.